AOD-9604 is a modified 16-amino-acid fragment of human growth hormone (residues 176–191), originally developed at Monash University and investigated through clinical trials as an anti-obesity drug. Those trials did not produce an approvable result—the compound did not receive FDA or TGA approval—so despite the fat-loss marketing, the AOD-9604 peptide remains unapproved. WADA lists it among prohibited substances in sport.

Safety note. This article is educational and for personal recordkeeping only. It gives no dose, unit count, concentration, reconstitution, injection technique, vendor, cycle, or stacking instructions. Peptide decisions, especially gray-market or research-use products, belong with a licensed professional.

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone — the so-called 176-191 fragment — originally investigated as an anti-obesity drug. That investigation did not lead to approval, so despite the fat-loss marketing, the AOD-9604 peptide is not an FDA-approved medicine. It is sold as a research-use-only product, and the FDA has flagged safety-information gaps for compounded versions.

That gap between the marketing and the regulatory record is the first thing to notice. A beginner may see AOD-9604 framed as targeted fat loss, when the human evidence is limited and the World Anti-Doping Agency lists it among prohibited substances. For a broader safety frame, read Research Peptide Safety Questions Before You Start.

What do people use AOD-9604 for?

People most often mention AOD-9604 for body recomposition, stubborn fat, weight management, and stacking with GLP-1 or other metabolic products. Those are community claims, not proof. The same claim can mean very different things depending on whether it comes from a clinical label, a small trial, an animal model, a vendor page, or a forum anecdote.

Use the claim as a filing label, not a conclusion. Write down the purpose in plain language: what outcome is being watched, what else changed at the same time, and what would count as a reason to stop and ask for care.

How do people discuss using AOD-9604?

Reported use usually means research-use listings, fat-loss protocol posts, and stack comparisons that often overstate what human trials can prove. The useful part to record is context, not numbers: why it was considered, who reviewed it, what else was already in the stack, and what stop signs were discussed.

Do not copy online calculators, vendor protocols, or preparation walkthroughs into a personal plan. A peptide protocol log should preserve professional guidance and observations, not turn a social post into instructions.

What does the research say?

FDA safety material identifies AOD-9604 as a substance with limited safety information and possible significant risks in compounding. WADA lists AOD-9604 in its prohibited peptide categories.

A good research note separates mechanism, animal data, human trial data, approval status, and real-world anecdotes. When those buckets get mixed together, a peptide can look more proven than it is.

What should a beginner track?

Track baseline weight trends, nutrition and training context, medication changes, adverse symptoms, and whether any result could be explained by diet, GLP-1 therapy, or other variables.

In Dosefi, keep the entry boring and complete: date, category, source type, professional guidance, symptoms, photos only when useful, and the question you want answered next. A clear log is not proof that the peptide works. It is a way to avoid rewriting the story after the fact.

What red flags matter most?

The biggest risk is assuming a fragment name means targeted fat loss without broader uncertainty. Unknown product quality, unclear clinical benefit, and sport eligibility all matter.

Also pause when a product is sold only through anonymous vendors, when a blend hides individual ingredients, when the seller offers medical claims without medical oversight, or when the only evidence is a before-and-after post. Serious symptoms should be handled as health events, not as content to troubleshoot in comments.

Sources